
Conference Coverage
Latest News

Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD

OnabotulinumtoxinA Meets Primary End Point in Phase 2 ELATE Trial for Upper Limb Essential Tremor

Episode 152: Building Safer, Smarter, and More Personalized Epilepsy Care

NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial

How Exome and Genome Sequencing Are Transforming Neurologic Diagnosis

Shorts










Videos
Podcasts
Continuing Medical Education
All News

At the 2025 CNS Annual Meeting, Craig Press, MD, discussed tailoring neuroICU treatment for pediatric patients, advances in seizure management, and how multidisciplinary collaboration can improve outcomes.

New real-world data presented at MDS 2025 demonstrated that foslevodopa/foscarbidopa reduced motor fluctuations and improved quality of life in patients with advanced Parkinson disease over 6 months.

Apitegromab, an invesigational muscle-targeting treatment, showed promising results in improving motor function among young patients with SMA in a phase 2 trial.

In this post-meeting Q&A, Claire Henchcliffe, MD, PhD, president-elect of the AALN, shared her reactions to AALN’s second annual meeting, the conversations that mattered most, and how the group plans to broaden and support neurology leadership in the year ahead.

PMD Alliance unveils a revamped website, enhancing accessibility and resources for the movement disorder community as it celebrates its 10th anniversary.

Johan Luthman, executive vice president and head of R&D at Lundbeck, discussed the rationale behind amlenetug, its mechanism of action, and the company’s ongoing efforts in multiple system atrophy through the phase 3 MASCOT trial.

Roche's Elecsys pTau181 test receives FDA clearance, revolutionizing Alzheimer diagnosis in primary care with a minimally invasive blood test.

Denali Therapeutics prepares for potential FDA approval of tividenofusp alfa, a groundbreaking therapy for Hunter syndrome, with a revised review date set.

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeutic benefit in more advanced forms of multiple sclerosis.

Trofinetide shows significant real-world improvements in Rett syndrome symptoms for pediatric and adult patients, enhancing communication and quality of life.

Allison W. Willis, MD, MS, associate professor of neurology at the University of Pennsylvania School of Medicine, provided an overview of hot topics from the ANA 2025 program.

Here's some of what is coming soon to NeurologyLive® this week.

Robert Shin, MD, FAAN, professor of neurology and ophthalmology at the University of Virginia and director of the UVA MS and Clinical Neuroimmunology Center, recently shared his expertise on how multiple sclerosis (MS) affects men on the National MS Society’s Ask an MS Expert program.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on gene therapy for Duchenne muscular dystrophy.